General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis Corporation(MODEST), AKCEA(MODEST), Regeneron(MODEST), IONIS(SIGNIFICANT), NewAmsterdam Pharma(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Amgen(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Regeneron(SIGNIFICANT), Arrowhead Pharmaceuticals(SIGNIFICANT), IONIS(SIGNIFICANT), New Amsterdam(SIGNIFICANT), Esperion(SIGNIFICANT), 89Bio(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Esperion(NONE), IONIS(SIGNIFICANT)

View Full Disclosure